Brief: Active Biotech AB Q3 Operating Loss Widens To SEK 9.3 Mln

Active Biotech AB publ

14/11/2019 07:35

Nov 14 (Reuters) - Active Biotech AB  ACTI.ST :
    * REG-ACTIVE BIOTECH INTERIM REPORT JANUARY – SEPTEMBER 2019
    * Q3 NET SALES SEK 0,9 MILLION VERSUS SEK 4.7 MILLION YEAR
AGO
    * A NEW BUSINESS PLAN FOR LAQUINIMOD AND TASQUINIMOD, BASED
ON
EXTENSIVE PRECLINICAL AND CLINICAL DATA PREVIOUSLY GENERATED, IS
IN PROGRESS
    * Q3 OPERATING LOSS SEK 9.3 MILLION VERSUS LOSS SEK 6.7
MILLION
YEAR AGO
    * DATA ON LAQUINIMOD FROM PHASE 2 LEGATO-HD STUDY IN
HUNTINGTON'S
DISEASE WAS PRESENTED AT INTERNATIONAL CONGRESS OF PARKINSON'S
DISEASE AND MOVEMENT DISORDERS

Source text for Eikon:  ID:nGNE2ZD7yX 
Further company coverage:  ACTI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))